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Serologic cross-reactivity between orthopoxviruses is 
a substantial barrier to laboratory diagnosis of speciﬁ  c or-
thopoxvirus infections and epidemiologic characterization of 
disease outbreaks. Historically, time-consuming and labor-
intensive strategies such as cross-adsorbed neutralization 
assays, immunoﬂ   uorescence assays, and hemagglutina-
tion-inhibition assays have been used to identify orthopoxvi-
rus infections. We used cross-adsorption to develop a sim-
ple and quantitative postadsorption ELISA for distinguishing 
between monkeypox and vaccinia infections. Despite the 
difﬁ  culty of diagnosing clinically inapparent monkeypox in 
previously vaccinated persons, this technique exhibited 
100% sensitivity and 100% speciﬁ  city for identifying clini-
cally overt monkeypox infection irrespective of vaccination 
history. We also describe a Western blot technique in which 
up to 3 diagnostic bands may be used to distinguish be-
tween vaccinia and monkeypox infection. The techniques 
described provide independent diagnostic tests suitable for 
retrospective analysis of monkeypox outbreaks.
H
uman monkeypox is a zoonotic disease found in re-
mote areas of western and central sub-Saharan Africa 
and is an important public health issue in these areas (1,2). 
Clinical symptoms monkeypox can be similar to those of 
chickenpox (caused by varicella-zoster virus), and these 
symptoms can cause difﬁ  culties in diagnosing cases on the 
basis of clinical symptoms alone (2,3). These symptoms 
can also vary among persons; most American patients in 
the 2003 monkeypox outbreak had a rash with 1 to >100 
skin lesions (4–7), whereas others had monkeypox infec-
tion without exanthem (8,9). Moreover, adults with pre-
existing immunity from childhood smallpox vaccinations 
may experience milder symptoms (5,10) or no symptoms 
(6). Standard clinical algorithms (11,12) may fail to iden-
tify these mild or asymptomatic cases; likewise, they are 
difﬁ  cult to conﬁ  rm by virologic methods because of the ab-
sence of skin lesions. Because of the extensive variability 
in clinical symptoms and common misdiagnosis as chick-
enpox, developing multiple diagnostic techniques that can 
be used to identify and conﬁ  rm monkeypox is crucial.
We describe 2 serologic techniques for diagnosing 
monkeypox infection. These techniques were based on di-
agnostic approaches such as radioimmunoassays and neu-
tralization assays that used a preadsorption step to remove 
or reduce cross-reactive orthopoxvirus antibodies before 
detection of species-speciﬁ  c antiviral antibodies (13–15). 
These basic ELISA and Western blot methods will be use-
ful for orthopoxvirus-speciﬁ  c serosurveys and retrospec-
tive analysis of monkeypox outbreaks.
Materials and Methods
Participants
Adults previously characterized as having suspected, 
probable, or conﬁ   rmed cases of monkeypox during the 
2003 Wisconsin monkeypox outbreak (4) provided in-
formed written consent and completed a medical history 
questionnaire before participation in our previous study 
(6). Monkeypox conﬁ  rmation was based on the standard 
case deﬁ  nition and conﬁ  rmation by the Centers for Disease 
Control and Prevention (CDC) in Atlanta, Georgia, USA, 
during the outbreak (4) or by subsequent immunologic tests 
(6) Participants were grouped according to vaccination his-
tory (Table). Samples from 13 unvaccinated monkeypox-
immune persons and 8 vaccinated monkeypox-immune 
persons were assessed. Of the 8 vaccinated persons, 3 had 
clinically inapparent cases and were not aware of hav-
ing been infected with monkeypox because of no notice-
able disease symptoms (6). However, these are described 
as laboratory-conﬁ  rmed cases of monkeypox on the basis 
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of multiple immunologic assays (6) (Table). Control par-
ticipants included recent primary smallpox vaccinees (n = 
10), revaccinated persons (n = 10) examined 2–4 months 
postvaccination, long-term immune smallpox vaccinees 
examined 20–40 years postvaccination (n = 10), and un-
vaccinated orthopoxvirus-naive persons (n = 12). Heparin-
ized blood was centrifuged over Histopaque-1077 (Sigma, 
St. Louis, MO, USA), and plasma was collected and stored 
at –80°C. Studies involving human participants were re-
viewed and approved by the Institutional Review Board for 
Oregon Health and Science University.
Viruses and Cells
Monkeypox virus (Zaire strain) and vaccinia virus 
(Western Reserve strain) were grown in BSC40 cells by 
using a multiplicity of infection of 0.1 and harvested at 48 
h postinfection. Cells were lysed by 3 freeze/thaw cycles 
in 10 mmol/L Tris, pH 8.0, and used as a virus lysate for 
preadsorption in ELISA and Western blots. Where indi-
cated, monkeypox and vaccinia viruses were also puriﬁ  ed 
by ultracentrifugation through 36% sucrose at 40,000 × g 
for 80 min, followed by band extraction after 25%–40% 
sucrose gradient sedimentation (33,000 × g for 40 min). 
Protein concentration was measured by the modiﬁ  ed Low-
ry assay (Pierce, Rockford, IL, USA). Puriﬁ  ed virus was 
inactivated for 2 h at 56°C; viral lysates were inactivated 
with 3% H2O2 at room temperature for 2 h. Uninfected 
BSC40 cell lysate was treated similarly to the infected cells 
described above.
Postadsorption ELISA
High protein-binding ELISA plates (Corning-Costar, 
Corning, NY, USA) were coated with an optimized con-
centration of H2O2-inactived monkeypox-infected BSC40 
cell lysate. Plasma samples were preadsorbed with equiva-
lent (6 ×108 PFU/mL) concentrations of H2O2-inactived 
monkeypox or vaccinia whole-cell lysate at a 1:30 dilution 
(5 μL plasma in 145 μL viral lysate) for 30 min at 37°C. 
Nonadsorbed samples were similarly treated with ELISA 
blocking buffer (phosphate-buffered saline containing 5% 
nonfat dry milk and 0.05% Tween 20). Samples were then 
added directly to ELISA plates, serially diluted in blocking 
buffer, and incubated at room temperature for 1 h. As a 
precaution against human blood-borne pathogens, samples 
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Table. Comparison of monkeypox-specific diagnostic tests* 
Serologic techniques  Postadsorption Western blot†  Patient
no. Paired IgG  Peptide ELISA 
Cellular 
techniques
Direct viral 
detection
Postadsorption
ELISA 39 kDa  124 kDa  148 kDa 
Monkeypox 
447 CC C C C + + +
452 CC C C C + + +
453 CC C P / S C + + +
461 CC C N A C + +
462 CC C C C +
481 CC C N A C + +
482 CC C N A C + +
484 CC C N A C +
489 CC C N A C + +
473 CC C N A C + +
519 C C CCC + +
520 C C CCC + +
557 ND ND ND NA C + + +
Vaccinia–monkeypox 
446‡ CC C N D U
449‡ C C UN DU+
450 CC C P / S C +
451 CC C C C +
454 CC C P / S C + + +
455‡ C C CN DU+
463 CC C C C +
500 C C CN DC +
*These studies are based on persons who were infected with monkeypox during the 2003 outbreak in Wisconsin and who were tested by 
independent laboratories by using serologic (6), cellular (4), and virologic (6) techniques. Serologic techniques included identification of monkeypox 
peptide-specific immunoglobulin (Ig) G by peptide ELISA and kinetic analysis of IgG to orthopoxvirus in paired plasma samples (2–4 mo and 1 y 
postinfection) by endpoint ELISA. Orthopoxvirus-specific CD8+ T cells were measured by using intracellular cytokine staining analysis. Plasma 
samples were obtained 2–4 mo postinfection, except for patients 473 and 500 (6 mo), 519 and 520 (12 mo), and 557 (30 mo). Virologic 
confirmation was obtained by viral culture, PCR, electron microscopy, and immunohistochemical analysis of tissue samples (4). C, confirmed; P/S, 
probable/suspected; NA, not available; ND, not done; U, unconfirmed. 
†If at least 5/6 analysts scored the band of interest as positive, + indicates positive identification of each specific diagnostic band. 
‡Clinically inapparent monkeypox infection in previously vaccinated persons as determined by cellular and serologic retrospective diagnostic 
techniques (12).RESEARCH
were then treated with 3% H2O2 (ﬁ  nal concentration) for 
an additional 30 min. After washing, horseradish peroxi-
dase–conjugated mouse antihuman immunoglobulin (Ig) 
G monoclonal antibody (clone G18–145; BD Pharmingen, 
San Diego, CA, USA) was added to the wells. Plates were 
washed after 1 h and detection reagents were added. Sub-
strate was prepared (o-phenylenediamine; Sigma-Aldrich, 
St. Louis, MO, USA) and diluted to a concentration of 0.4 
mg/mL in 0.05 M citrate, pH 5.0, and H2O2 was added (ﬁ  -
nal concentration of 0.01%). Color was developed for at 
least 20 min before the reaction was stopped by adding 1 M 
HCl; plates were read at 490 nm. 
Antibody titers were determined by log-log transfor-
mation of the linear portion of the dilution curve with 0.1 
optical density units used as the endpoint, and transforma-
tion was performed on ﬁ  nal values (6). For an Excel (Mi-
crosoft, Redmond, WA, USA) ﬁ  le containing a template of 
these calculations, please contact the corresponding author, 
or see the example given in the online Technical Appen-
dix (available from www.cdc.gov/EID/content/14/4/592-
Techapp.pdf).
Differential Western Blot
Western blot procedures were performed with the fol-
lowing modiﬁ  cations. Two micrograms of gradient-puriﬁ  ed 
monkeypox or vaccinia virus was separated by 4%–20% 
Tris-glycine gradient sodium dodecyl sulfate–polyacryl-
amide electrophoresis (SDS-PAGE) (Invitrogen, Carlsbad, 
CA, USA) under reducing conditions. Equivalent protein 
loading was conﬁ  rmed on representative gels by staining 
with GelCode Blue (Pierce).
Proteins were electrophoretically transferred to polyvi-
nylidene ﬂ  uoride membranes (Invitrogen), and membrane 
strips with 3 lanes containing a molecular mass standard 
(SeeBlue Plus 2; Invitrogen), monkeypox, and vaccinia 
were blocked with phosphate-buffered saline containing 
1% Tween 20 and 5% nonfat dry milk. Plasma was diluted 
1:20 in uninfected cell lysate or H2O2-inactived vaccinia 
lysate (adjusted to a concentration of 2.5 mg/mL total pro-
tein) for 30 min at 37°C. Adsorbed plasma was adjusted to 
a 1:10,000 dilution in 10 mL of blocking buffer and incu-
bated with membranes overnight in 50-mL conical tubes 
at 4°C with rocking. After 3 washes in blocking buffer, re-
active bands were identiﬁ  ed with horseradish peroxidase–
conjugated goat antihuman IgG (γ chain speciﬁ  c; Jackson 
ImmunoResearch, West Grove, PA, USA) by using chemi-
luminescent detection (SuperSignal West Dura Substrate; 
Pierce). Plasma from the same monkeypox patient was 
used as a positive control in each experiment to identify the 
position of diagnostic bands. Blots were exposed to x-ray 
ﬁ  lm until diagnostic bands were clearly visible, and other 
ﬁ  lms were then overexposed to ensure that any low-inten-
sity bands were given ample opportunity to appear. Plasma 
from some orthopoxvirus-naive persons did not react with 
any monkeypox or vaccinia protein bands. In these instanc-
es, ﬁ  lms were exposed 10× longer than the last readable 
positive control exposure before a negative result was re-
corded. Films were scanned and the positions of diagnostic 
bands were indicated on the basis of the positive control. 
Analysts scored the vaccinia-preadsorbed Western blots 
for the 39-kDa, 124-kDa, and 148-kDa diagnostic bands 
as present only in the monkeypox lane, absent from the 
monkeypox lane, present in the monkeypox and vaccinia 
lanes (i.e., experimental equivocal), or technical equivocal 
caused by nonspeciﬁ  c background. Immunoreactive bands 
deemed experimental equivocal were counted against the 
sensitivity or speciﬁ  city of the assay. Blots containing tech-
nical equivocal data were repeated, and analysts rescored 
bands that were unreadable in the initial screen before de-
termining ﬁ  nal sensitivity and speciﬁ  city..
Results
Postadsorption ELISA
Orthopoxviruses have highly conserved genomes (16), 
which results in high levels of antibody cross-reactivity. 
However, viruses such as monkeypox also contain genes 
that are absent, mutated, or truncated in vaccinia; these gene 
products can be used to distinguish between monkeypox 
and vaccinia infections (6,17–21). The concentration of vi-
ral antigen used in the preadsorption step of the ELISA was 
determined by using high-titer plasma from 2 recently vac-
cinated vaccinia-immune persons obtained at the peak (day 
21) of the anamnestic response with ELISA titers that were 
≈10-fold higher than the highest convalescent-phase sam-
ples used in the rest of the experiments. Two of the highest 
titer samples from monkeypox-immune persons (obtained 
at 2 months postinfection) were also used in these prelimi-
nary studies (online Technical Appendix). These samples 
provided a rigorous test of homologous and heterologous 
antigens to deplete antiviral antibodies before performing 
the ELISA. Titration of virus antigen indicated that lysates 
normalized to contain 6 × 108 PFU equivalents/mL were 
best for differentiating between vaccinia and monkeypox 
infections.
Orthopoxvirus-naive persons or persons infected with 
monkeypox or vaccinia were then tested to establish the 
diagnostic validity of this approach by using monkeypox-
coated ELISA plates (Figure 1, panel A). If plasma from 
a representative monkeypox-immune person was preincu-
bated with vaccinia antigen, virus-speciﬁ  c antibody titers 
decreased (from 39,904 ELISA units [EU] to 13,912 EU). 
However, if the sample was preincubated with an equiva-
lent amount of monkeypox antigen before performing the 
ELISA (2,542 EU), monkeypox antibody titers decreased 
substantially. For the data of the monkeypox-immune 
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person shown in Figure 1, panel A, there was a 5.5-fold dif-
ference (13,912 EU divided by 2,542 EU) in the ability of 
monkeypox antigen to reduce monkeypox-speciﬁ  c antibody 
levels than vaccinia antigen. For persons who were vaccinia 
immune but still had contracted clinically apparent monkey-
pox disease, the difference in postadsorption ELISA titers 
was typically smaller (3.2-fold difference in the example 
shown in Figure 1, panel A), but the difference still demon-
strated a clear distinction between preadsorption with mon-
keypox or vaccinia antigens. If a person had been infected 
with only vaccinia or revaccinated with vaccinia, there was 
essentially no difference in the ability of monkeypox antigen 
to deplete antiviral antibodies than an equivalent amount of 
vaccinia antigen on a monkeypox-coated ELISA plate. In 
contrast, orthopoxvirus-naive persons were seronegative by 
ELISA and can be easily distinguished from monkeypox-
immune or vaccinia-immune persons because they score be-
low the limits of detection by ELISA (<100 EU) without any 
preadsorption steps required.
To determine whether the difference in postadsorp-
tion ELISA results could be used effectively to distinguish 
between vaccinia and monkeypox infections, we plotted 
the results from primary monkeypox-immune persons, 
previously vaccinated monkeypox immune persons, pri-
mary vaccinia-immune persons, and revaccinated vaccinia-
immune persons (Figure 1, panel B). We established a di-
agnostic cutoff of 2.5 by plotting the difference in postad-
sorption ELISA titers for each group. To establish the di-
agnostic cutoff, we used persons with laboratory-conﬁ  rmed 
cases of primary monkeypox (6) as positive controls and 
vaccinia-immune persons with no evidence of monkeypox 
infection as negative controls (Figure 1, panel B). The 2.5-
fold difference in postadsorption ELISA titers provided the 
best balance of high sensitivity (100% positive for primary 
monkeypox) and high speciﬁ   city (0% positive for vac-
cinia immune). Other diagnostic cutoff values resulted in 
decreased speciﬁ  city or sensitivity when these 2 divergent 
groups of positive and negative controls were compared. 
For example, a diagnostic cutoff of 3.0 reduced the sensi-
tivity of the assay to 93% (12/13) for primary monkeypox 
but did not affect the speciﬁ  city (100%). Conversely, a di-
agnostic cutoff of 2.0 did not affect sensitivity (100%) but 
decreased speciﬁ  city from 100% to 90% (i.e., 18/20 vac-
cinia-immune persons were positive). Vaccinia-immune 
monkeypox patients typically had lower differences in 
postadsorption ELISA titers. The lower difference suggests 
that preexisting immunity to vaccinia may have resulted in 
a lower induction of monkeypox species-speciﬁ  c antibody 
responses and is consistent with the results of our previous 
study (12).
Using the established 2.5-fold diagnostic cutoff, we 
achieved 100% (13/13) sensitivity for detecting primary 
monkeypox infection and 63% (5/8) sensitivity for detecting 
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Figure 1. Diagnosis of monkeypox by postadsorption ELISA. 
Plasma samples were obtained from monkeypox-immune persons 
(2–30 months postinfection), vaccinia-immune persons (2–4 
months postinfection), or uninfected orthopoxvirus-naive persons 
and tested on ELISA plates coated with inactivated monkeypox 
antigen. A) A representative monkeypox-speciﬁ   c ELISA with 
plasma samples from an unvaccinated monkeypox-infected person 
(MPV), a previously vaccinated (i.e., vaccinia-immune) monkeypox-
infected person (VV-MPV), a vaccinia-immune person (VV), a 
vaccinia-immune person who was revaccinated with vaccinia (VV-
VV), and an uninfected orthopoxvirus-naive person (OPV-naive). 
Plasma was not preadsorbed (∅, gray bars), preadsorbed with 
inactivated vaccinia antigen (black bars), or preadsorbed with 
inactivated monkeypox antigen (white bars) before ELISA on 
monkeypox-coated plates. Numbers above bars refer to differences 
in postadsorption MPV ELISA titers after adsorption with vaccinia 
antigen compared with adsorption with monkeypox antigen. Plasma 
from 1 orthopoxvirus-naive person (representative of n = 12) was 
not preadsorbed with viral antigen because it was seronegative 
(<100 ELISA units) and below our detection limit (dashed horizontal 
line). B) Plasma samples from monkeypox-infected persons (•, n 
= 13), vaccinia-immune monkeypox-infected persons (■, n = 8), 
vaccinia-immune persons (▲, n = 10), and revaccinated vaccinia-
immune persons (▼, n = 10) were tested by postadsorption ELISA. 
Data show fold-differences of monkeypox antibody titers after 
adsorption with vaccinia antigen compared with adsorption with 
monkeypox antigen. Dashed horizontal line indicates a diagnostic 
cutoff indicative of a positive result, which was determined as a 
postadsorption difference score of >2.5. *Denotes results of 
plasma samples obtained from persons with clinically inapparent 
monkeypox infection.RESEARCH
monkeypox infection in vaccinia-immune persons in which 
monkeypox was a heterologous orthopoxvirus infection. Of 
the 8 vaccinia-immune persons with monkeypox, 3 were 
clinically asymptomatic but were previously identiﬁ  ed by 
serologic and cellular techniques (6). However, these cas-
es are more difﬁ  cult to diagnose on the basis of serologic 
analysis only (6) and could not be identiﬁ  ed by the post-
adsorption ELISA (Figure 1, panel B; Table). However, 
if only persons with clinically overt monkeypox infection 
were included in the analysis, 100% (5/5) of secondary 
monkeypox infections were identiﬁ  ed by this assay (Fig-
ure 1, panel B; Table). We also observed 100% speciﬁ  city; 
20/20 vaccinia-immune controls (10 primary and 10 boost-
er smallpox vaccinations) and 12/12 orthopoxvirus-naive 
persons were negative by this postadsorption ELISA. We 
report 86% (18/21) overall sensitivity for detecting mon-
keypox, 100% (18/18) sensitivity for conﬁ  rming clinically 
overt monkeypox, and 100% (32/32) speciﬁ  city with this 
approach.
Differential Western Blot
To more easily recognize uniquely reactive monkey-
pox-speciﬁ  c bands by Western blot and simplify interpre-
tation of this serologic diagnostic technique, we added an 
adsorption step to reduce cross-reactive antibodies to or-
thopoxvirus. Separation of 2 μg of puriﬁ  ed vaccinia and 
monkeypox by 4%–20% gradient SDS-PAGE resulted in 
good separation of protein bands across a broad spectrum 
of molecular masses (Figure 2, panel A) and effective 
transfer of separated proteins to the polyvinylidene ﬂ  uoride 
membrane. Protein-banding patterns of monkeypox virus 
and vaccinia virus are similar, but a protein band of ≈39 
kDa is visible in the monkeypox lane of the GelCode Blue-
stained SDS-PAGE that is missing from the vaccinia lane. 
Incubation of immune plasma in a 20-fold volume excess 
of virus antigen (1 μL plasma plus 19 μL vaccinia-infected 
cell lysate at 6 × 108 PFU equivalents/mL) before perform-
ing the Western blot effectively reduced the intensity and 
detection of cross-reactive bands (Figure 2, panel B). 
Diagnostic bands with apparent molecular masses of 
148, 124, and 39 kDa were identiﬁ  ed when monkeypox-
immune plasma was used, but were not observed after 
Western blot analysis with plasma samples from a repre-
sentative vaccinia-immune person (Figure 2, panel C) or 
an orthopoxvirus-naive person (Figure 2 , panel D). Be-
cause orthopoxvirus-naive persons were seronegative by 
ELISA (Figure 1, panel A), the Western blot example 
shown in Figure 2, panel D, required a 1-hour exposure 
to identify any faint bands after vaccinia antigen adsorp-
tion. In contrast, samples from monkeypox-immune and 
vaccinia-immune persons were exposed to ﬁ  lm for 5 s to 
2 min for optimal identiﬁ  cation of virus-speciﬁ  c banding 
patterns. We did not observe a correlation between viral 
protein levels determined by SDS-PAGE (Figure 2, panel 
A) and immunodominance by Western blot analysis (Fig-
ure 2, panel B). 
Unblinded analysis of the Western blots was ﬁ  rst per-
formed by 2 independent analysts who had access to pa-
tients’ medical histories (Figure 3, panel A). Reactivity to 
the 39-kDa band resulted in 100% sensitivity for identi-
fying primary monkeypox infection and 75% sensitivity 
for identifying secondary monkeypox infection. However, 
20%–30% of the negative control samples (vaccinia pri-
mary, vaccinia long-term, and orthopoxvirus naive) also re-
acted with this band, which resulted in a speciﬁ  city of only 
70%–80% (76% overall speciﬁ  city). The 124-kDa band 
showed 96% sensitivity for identifying primary monkey-
pox infection but only 31% sensitivity for identifying sec-
ondary monkeypox infection. However, this protein was 
more speciﬁ  c than the 39-kDa protein; 0%–10% of nega-
tive controls showed reactivity (97% overall speciﬁ  city). 
The 148-kDa band showed low diagnostic sensitivity; only 
37%–46% of plasma samples from monkeypox-immune 
persons reacted with it in Western blot analysis. Converse-
ly, the 148-kDa band showed high speciﬁ  city with 0%–5% 
of negative control plasma that were positive (i.e., over-
all speciﬁ  city >97%). Other bands were also identiﬁ  ed as 
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Figure 2. Development of a monkeypox (MPV)–speciﬁ  c diagnostic 
assay using Western blot analysis. Adsorption of cross-reactive 
orthopoxvirus antibodies with vaccinia antigen before Western 
blot analysis provided easier identiﬁ  cation of monkeypox-speciﬁ  c 
bands. A) Two micrograms of sucrose gradient–puriﬁ  ed monkeypox 
virus or vaccinia virus (VV) were separated by sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (4%–20% gels) and 
stained with GelCode Blue (Pierce, Rockford, IL, USA) to compare 
banding patterns and conﬁ  rm equivalent protein loading. Proteins 
were electrophoretically transferred to polyvinylidene diﬂ  uoride 
membranes and probed with plasma from B) a monkeypox-immune 
person, C) a vaccinia-immune person, or D) an orthopoxvirus-naive 
person after adsorption of plasma with control antigen (uninfected 
H2O2-treated BSC40 cell lysate) or vaccinia antigen (H2O2-inactived 
vaccinia-infected BSC40 cell lysate). Immunoreactive bands were 
detected with peroxidase-conjugated antihuman immunoglobulin G 
plus chemiluminescent substrate and exposed to x-ray ﬁ  lm. Arrows 
indicate location of diagnostic bands with apparent molecular 
masses of 148, 124, and 39 kDa. Rectangles indicate locations of 
diagnostic bands.Retrospective Analysis of Monkeypox Infection
potential diagnostic indicators of monkeypox infection, 
such as the 98-kDa and 18-kDa bands (Figure 2, panels 
B and C; online Technical Appendix). However, further 
analysis showed that the 98-kDa band had low diagnostic 
potential (48% sensitivity and 72% speciﬁ  city), as did the 
18-kDa band shown in Figure 2, panel B (60% sensitivity 
and 66% speciﬁ  city).
Blinded analysts (n = 4) with no knowledge of infec-
tion history were asked to score Western blots to determine 
the feasibility of this approach under conditions in which 
background clinical information may not be available (Fig-
ure 3, panel B). Unblinded analysts reported somewhat 
higher sensitivity for each of the diagnostic bands and iden-
tiﬁ  ed the same or slightly lower speciﬁ  city when interpret-
ing Western blots with vaccinia-immune or orthopoxvirus-
naive plasma samples, but the overall results from blinded 
and unblinded analysis were similar.
Discussion
Historically, several serologic techniques have been 
used to identify orthopoxvirus infections, including hemag-
glutination-inhibition (13), gel precipitation (17,22,23), 
complement ﬁ  xation (22), cross-neutralization (14), immu-
noﬂ  uorescence (24,25), Western blot (26,27), radioimmu-
noassay (13,15), and ELISA (28,29). In previous studies, 
we used a peptide-based ELISA with peptide sequences 
from the monkeypox B21R gene to differentially diagnose 
monkeypox infection (6). This approach is highly sensi-
tive and speciﬁ  c for diagnosing monkeypox at 2–4 months 
postinfection. However, it is yet unknown how quickly 
peptide-speciﬁ  c antibody responses are mounted or how 
long they are maintained. Because multiple independent 
diagnostic techniques should be available for detecting 
virulent orthopoxvirus infections, we have developed the 
2 new assays.
Detection of virus-speciﬁ  c IgM by ELISA is often con-
sidered the most useful for conﬁ  rming a recent infection. 
An IgM capture ELISA for diagnosing monkeypox (29) 
was developed by using vaccinia virus as a surrogate an-
tigen for monkeypox, and the investigators reported 100% 
speciﬁ  city and 92% sensitivity. Per CDC monkeypox case 
deﬁ  nition, these cases had been conﬁ  rmed by direct viral 
detection including PCR, electron microscopy, virus iso-
lation, or immunohistochemistry. However, the reported 
speciﬁ  city and sensitivity were based on only a subset of 
samples obtained 5–77 days after onset of rash. Inclusion 
of samples beyond this range resulted in additional false-
negative results and a concomitant decrease in sensitivity. 
A further limitation of this study is that only virologically 
conﬁ  rmed monkeypox cases were included; persons with 
mild symptoms or vaccine-mediated subclinical infection 
were not examined.
A more recent study identiﬁ  ed 3 unvaccinated con-
tacts who were negative by IgM ELISA but positive by 
IgG ELISA despite no reported disease symptoms (10). If 
these contacts contracted monkeypox infections, then this 
would contradict our previous ﬁ  ndings in which unvac-
cinated monkeypox patients showed at least some, if not 
all, disease symptoms associated with monkeypox (6,8). It 
is difﬁ  cult to directly compare our results with these other 
reports (10,29) because different subsets of monkeypox pa-
tients were examined, different time points were analyzed, 
and different case deﬁ  nitions were used. For instance, the 
CDC case deﬁ  nition is based on a combination of clinical, 
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Figure 3. Diagnosis of monkeypox infection by Western blot analysis. 
Plasma samples from unvaccinated monkeypox-infected (2–30 
months postinfection) (MPV), vaccinia-immune monkeypox (2–6 
months postinfection) (VV-MPV), primary vaccinia-immune (2–4 
months postimmunization) (VV), long-term vaccinia-immune (>20 
years postimmunization) (VV long-term), and orthopoxvirus-naive 
(OPV) persons were analyzed by Western blot after adsorption 
with vaccinia-infected BSC40 cell lysate to reduce cross-reactive 
antibodies as described in Figure 2. Immunoreactivity to diagnostic 
protein bands of ≈39 kDa, 124 kDa, and 148 kDa was assessed by 
A) unblinded analysts with knowledge of subject medical history (n 
= 2) and B) blinded analysts who did not have knowledge of subject 
medical history (n = 4). Findings of each analyst were averaged for 
each person and percentages shown represent a composite of all 
data points.RESEARCH
epidemiologic, and laboratory criteria (www.cdc.gov/nci-
dod/monkeypox/casedeﬁ  nition.htm); on the basis of these 
criteria, monkeypox infection can only be conﬁ  rmed if vi-
rus is detected. 
We used epidemiologic criteria (i.e., direct or indi-
rect exposure to monkeypox-infected animals or humans) 
in addition to laboratory criteria with high sensitivity and 
speciﬁ  city (6). This approach led to identiﬁ  cation of per-
sons in whom monkeypox exposure and disease symptoms 
occurred, but only immunologic and not virologic labora-
tory analysis could be performed. Moreover, we identiﬁ  ed 
3 previously vaccinated persons who were exposed to mon-
keypox and showed immunologic evidence of infection 
(6). However, because they did not show clinical disease 
symptoms, they would not meet CDC case deﬁ  nition for 
monkeypox.
Depletion of cross-reactive antibodies by preadsorp-
tion before ELISA enabled the identiﬁ  cation of clinically 
apparent monkeypox infection with 100% sensitivity and 
100% speciﬁ  city. However, 1 limitation was that we were 
unable to identify clinically inapparent monkeypox infec-
tion in previously vaccinated persons (Figure 1, Table). 
These persons were not tested by virologic methods but 
were conﬁ  rmed by immunologic techniques such as early 
versus late analysis for antibodies to orthopoxvirus, mon-
keypox B21R peptide ELISA, or orthopoxvirus-speciﬁ  c T-
cell analysis (6). In our previous study (6) and this study, 
persons with high antiviral immunity from smallpox vacci-
nations were more likely to mount anamnestic responses to 
cross-reactive vaccinia epitopes rather than to monkeypox. 
This may be caused by more limited monkeypox replica-
tion, which resulted in fewer disease symptoms (6) and less 
antigenic stimulation of antibody responses to novel virus 
epitopes. Despite the difﬁ  culties involved with serologic 
diagnosis of clinically asymptomatic cases of monkeypox, 
the postadsorption ELISA described here provides a robust 
method for distinguishing between vaccinia and clinically 
overt monkeypox infections.
Our modiﬁ   ed Western blot technique provides an 
additional independent test for laboratory conﬁ  rmation 
of orthopoxvirus infection. It has only modest value as a 
stand-alone diagnostic test because of <90% sensitivity and 
speciﬁ  city overall, but may be useful for conﬁ  rming cases 
of monkeypox identiﬁ  ed by other virologic or serologic 
approaches. Relative to standard Western blot approaches 
(26,27), preadsorption of plasma with vaccinia antigens 
decreased the intensity and detection of cross-reactive 
proteins and enabled easier identiﬁ  cation of 3 diagnostic 
protein bands (39, 124, and 148 kDa). In this assay, 95% 
(20/21) of monkeypox-immune participants (including 2/3 
who had clinically inapparent cases) reacted with at least 
1 diagnostic protein band. A cluster of 33 kDa- to 42 kDa-
vaccinia proteins was previously described as immunore-
active with pooled human vaccinia immune globulin (27). 
This cluster was also evident in the current study (Figure 2, 
panels B and C), although detection and intensity of bands 
within this cluster varied among persons. The 39-kDa mon-
keypox diagnostic band was readily distinguishable from 
vaccinia-speciﬁ  c proteins. This band may represent a gene 
product that is unique to monkeypox, or alternatively it 
may be common to both viruses but modiﬁ  ed in a man-
ner that results in distinct migration characteristics. The 
immunoreactive protein bands identiﬁ   ed were effective 
in differentiating between monkeypox and vaccinia infec-
tion and may prove useful for identifying other virulent or-
thopoxviruses. Preliminary studies indicate that 5 (83%) of 
6 smallpox survivors can be retrospectively diagnosed by 
using this technique.
Serologic diagnostic techniques provide a broad win-
dow of detection relative to direct virus detection, which is 
limited to the period of active infection/virus replication. 
Only 37 of >72 suspected or probable cases of monkeypox 
were conﬁ  rmed by direct virologic methods during the US 
outbreak (www.cdc.gov/od/oc/media/mpv/cases.htm) (6). 
The US outbreak provided the ﬁ  rst identiﬁ  cation of human 
monkeypox outside Africa and showed the importance of 
monkeypox and other geographically limited zoonoses in 
an increasingly connected global community. Better diag-
nostics will help in measuring the effect of monkeypox in 
disease-endemic areas and will be important in effective 
outbreak detection during accidental or intentional release 
of virulent orthopoxviruses. We have described 2 indepen-
dent methods for serologic conﬁ  rmation of monkeypox in-
fection that will be useful for these purposes.
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